期刊
ONCOTARGET
卷 7, 期 28, 页码 44084-44095出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9857
关键词
esophageal adenocarcinoma; array CGH; prognosis; chemotherapy
资金
- Cancer Research UK [C26441/A8944]
- Royal Marsden/Institute of Cancer Research
- Center for Translational Molecular Medicine, DeCoDe project [03O-101]
- Academy of Medical Sciences (AMS) [AMS-SGCL7-West] Funding Source: researchfish
- National Institute for Health Research [CL-2011-02-004] Funding Source: researchfish
Neoadjuvant chemo(radio) therapy followed by surgery is the standard of care for patients with locally advanced resectable esophageal adenocarcinoma (EAC). There is increasing evidence that drug resistance might be related to genomic heterogeneity. We investigated whether genomic tumor heterogeneity is different after cytotoxic chemotherapy and is associated with EAC patient survival. We used arrayCGH and a quantitative assessment of the whole genome DNA copy number aberration patterns ('DNA copy number entropy') to establish the level of genomic tumor heterogeneity in 80 EAC treated with neoadjuvant chemotherapy followed by surgery (CS group) or surgery alone (S group). The association between DNA copy number entropy, clinicopathological variables and survival was investigated. DNA copy number entropy was reduced after chemotherapy, even if there was no morphological evidence of response to therapy (p<0.001). Low DNA copy number entropy was associated with improved survival in the CS group (p=0.011) but not in the S group (p=0.396). Our results suggest that cytotoxic chemotherapy reduces DNA copy number entropy, which might be a more sensitive tumor response marker than changes in the morphological tumor phenotype. The use of DNA copy number entropy in clinical practice will require validation of our results in a prospective study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据